Company Overview of Altus Pharmaceuticals Inc.
On January 22, 2013, Altus Pharmaceuticals Inc went out of business as per its Chapter 7 liquidation filing under bankruptcy. Altus Pharmaceuticals Inc., together with its subsidiaries, focuses on the development and commercialization of oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders. Its lead product candidates include ALTU-238, completed Phase II clinical trial in adults, is a crystallized formulation of human growth hormone for the treatment of hormone deficiency and related disorders; and ALTU-237, completed Phase I clinical trial, which is used for the treatment of hyperoxalurias and kidney stones. The company’s preclinical research a...
610 Lincoln Street
Waltham, MA 02451
Founded in 1992
Key Executives for Altus Pharmaceuticals Inc.
Altus Pharmaceuticals Inc. does not have any Key Executives recorded.
Altus Pharmaceuticals Inc. Key Developments
SEC Revokes Registration Of Securities Of Altus Pharmaceuticals
Sep 18 13
An Administrative Law Judge issued an Order Making Findings and Revoking Registrations as to Altus Pharmaceuticals, Inc. by Default (Default Order). The Default Order found that the company has securities registered with the Securities and Exchange Commission (SEC) pursuant to Section 12(g) of the Securities Exchange Act of 1934, failed to file required periodic reports, and that the evidence supported revocation of its registered securities as necessary or appropriate for the protection of investors.
SEC Orders Hearings On Registration Suspension Or Revocation Against Altus Pharmaceuticals, Inc. For Failure To Make Required Periodic Filings
Aug 14 13
In conjunction with trading suspension, Securities and Exchange Commission (SEC or the commission) also instituted public administrative proceedings to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of Altus Pharmaceuticals, Inc. for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company was delinquent in their required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceedings.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries